Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stereotactical PDT with 5-ALA in Recurrent Glioblastoma
NCT04469699Phase 2Terminated
- Sponsor
- Universitätsklinikum Münster
- Start
- Apr 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 5-aminolevulinic acid in glioblastoma (GBM), sponsored by Universitätsklinikum Münster. Started Apr 2021; status: terminated.
02
Drugs
5-aminolevulinic acid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04469699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04469699.